Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Guidelines for Molecular Testing in Biliary Tract Cancers

October 5th 2022

Panelists share their perspectives on molecular testing guidelines for patients diagnosed with biliary tract cancers.

FDA Approves Futibatinib for FGFR2+ Cholangiocarcinoma

September 30th 2022

The FDA has granted an accelerated approval to futibatinib (Lytgobi) for adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or other rearrangements.

Role of Locoregional Therapy in Early- or Intermediate-Stage HCC

September 30th 2022

Comprehensive insight on the role of locoregional therapies in early- or intermediate-stage HCC, alone or in combination with systemic agents.

Early- and Intermediate-Stage HCC Treatment Landscape

September 30th 2022

Opening their discussion on the management of hepatocellular carcinoma, expert panelists take a broad look at the treatment landscape.

Patient Profile 4: A Patient with HER2+ Gastric Cancer Treated With T-DXd Who Develops Diarrhea

September 29th 2022

Shifting focus to the second patient profile of HER2+ gastric cancer, key opinion leaders highlight the risk and management of diarrhea in this setting.

Ongoing Clinical Trials With T-DXd in HER2+ Gastric Cancer

September 29th 2022

Panelists briefly review ongoing clinical trials with trastuzumab deruxtecan in the setting of HER2+ gastric cancers.

Biliary Tract Cancers: Staging and Clinicopathologic Features

September 28th 2022

Comprehensive insight on staging biliary tract cancers followed by an overview of molecular testing and targetable clinicopathologic features.

Challenges in Diagnosing Biliary Tract Cancers

September 28th 2022

Expert perspectives on the presentation of biliary tract cancers with specific insight to the challenges inherent in reaching a timely diagnosis.

Intraperitoneal Chemotherapy Technique Aims to Dramatically Improve Outcomes in Gastric Carcinomatosis

September 22nd 2022

A novel approach to chemotherapy administration in advanced gastric cancer that has progressed to gastric carcinomatosis is poised to alter the treatment landscape and improve outcomes for this patient population.

T-DXd in HER2+ Gastric Cancer: Managing Neutropenia and Other AEs

September 22nd 2022

Focused discussion on the management of antibody drug conjugate–related adverse events in gastric cancer, with a focus on neutropenia.

First- and Second-Line Treatment Options for HER2+ Gastric Cancer

September 22nd 2022

A broad overview of the treatment armamentarium for patients receiving first- or second-line therapy for HER2+ gastric cancer.

Zanidatamab Zovodotin Showcases Promising Safety, Activity in HER2+ Solid Cancers

September 21st 2022

Zanidatamab zovodotin was found to produce encouraging responses and to have a manageable toxicity profile when used as a monotherapy in heavily pretreated patients with HER2-positive solid cancers.

Incidence and Risk Factors for Biliary Tract Cancers

September 21st 2022

Shared insight on the global incidence of biliary tract cancers and which risk factors most impact the likelihood of disease.

An Overview on Biliary Tract Cancers

September 21st 2022

Opening their discussion on biliary tract cancers, a multidisciplinary panel of experts consider how specific subsets of these malignancies differ from one another.

FDA Grants Orphan Drug Designation to ATG-101 for Pancreatic Cancer

September 19th 2022

The FDA has granted an orphan drug designation to the novel PD-L1/4-1BB bispecific antibody ATG-101 for the treatment of patients with pancreatic cancer.

FDA Grants Orphan Drug Designation to Ezurpimtrostat for Cholangiocarcinoma

September 19th 2022

The FDA has granted an orphan drug designation to the novel autophagy/palmitoyl protein thioesterase-1 inhibitor ezurpimtrostat for the treatment of patients with cholangiocarcinoma.

Immunotherapy Drives First-line Systemic Treatment for Advanced HCC

September 19th 2022

Evidence-based decisions have leveraged the use of immunotherapy combination atezolizumab plus bevacizumab for patients who receive a diagnosis of hepatocellular carcinoma.

FDA Grants Orphan Drug Status to SY-5609 for Pancreatic Cancer

September 16th 2022

The FDA has granted an orphan drug designation to the CDK7 inhibitor SY-5609 for use as a potential therapeutic option in patients with relapsed metastatic pancreatic cancer.

Atezolizumab and Bevacizumab TRAEs are Potential Predictors of Favorable Outcomes in HCC

September 16th 2022

Patients with hepatocellular carcinoma who developed treatment-related adverse effects associated with atezolizumab plus bevacizumab had improved overall survival and progression-free survival outcomes.

Patient Profile 3: A Patient with HER2+ Gastric Cancer Treated With T-DXd–who Develops Neutropenia

September 15th 2022

Centering discussion on a patient profile of HER2+ gastric cancer, experts in oncology discuss the occurrence of neutropenia with trastuzumab deruxtecan therapy.